Preliminary synthetic 5-MeO-DMT phase 2 results

The Microdose is an excellent free psychedelics newsletter. They report on a couple of recent 5-MeO-DMT publications, saying: "The hallucinogenic compound 5-MeO-DMT comes from the secretions of Bufo alvarius, also known as the Sonoran Desert toad. This week, two companies developing synthetic forms of the substance as medical treatments announced preliminary results. UK-based biotech company Beckley Psytech publicized initial findings from a phase IIa study of BPL-003, a synthetic nasal form of 5-MeO-DMT, in treating alcohol use disorder alongside cognitive behavioral therapy. (Beckley completed its phase I study of BPL-003 in late 2022, and reported that no serious adverse events resulted from its use.) The study included 12 people with moderate to severe alcohol use disorder, and was open-label, which means all participants knew they were receiving BPL-003 rather than a placebo. Beckley Psytech reported that the average amount of alcohol consumed by participants dropped after participants received a single dose of BPL-003 and therapy, and that half the participants had abstained from drinking in the 12 week follow-up period after their dosing session. Dublin-based biopharma company GH Research also announced positive preliminary results for GH001, a synthetic inhalable form of 5-MeO-DMT, in a phase IIb study in people with treatment-resistant depression. The study included 81 people, 40 of whom received GH001 and 41 who received a placebo. Unlike Beckley’s study, participants did not receive therapy alongside their dosing session. Overall, GH reported that participants who received GH001 showed a significant reduction in their depression symptoms a week after their dosing session, while participants in the placebo session showed a slight uptick in depression symptoms."

For more psychedelic news and research, visit the psychedelic health professional network homepage.